Login to Your Account



Clinic Roundup


Friday, January 20, 2012
• Genta Inc., of Berkeley Heights, N.J., reported results from its Phase IIb confirmatory trial of tesetaxel in 41 patients with advanced gastric cancer who progressed on at least one prior chemotherapy regimen that included a platinum compound (cisplatin, oxaliplati or carboplatin) and a fluoropyrimidine compound (5-fluorouracil or capecitabine [Xeloda, Hoffman-La Roche]).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription